Stock Track | GRAIL Soars 22.53% on Positive Q1 Results and Encouraging Cancer Detection Trial Data

Stock Track

May 14, 2025

Shares of GRAIL, Inc. (NASDAQ: GRAL) surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.

GRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million for the quarter, investors were encouraged by the strong top-line growth and the company's improving financial position.

Adding to the optimism, GRAIL announced positive top-line results from the prevalent screening round of the NHS-Galleri trial. The company reported a substantially higher positive predictive value (PPV) than previously observed in the PATHFINDER study. This data suggests improved accuracy in GRAIL's multi-cancer early detection (MCED) technology, potentially strengthening its position in the cancer diagnostics market. The company plans to share registrational data from the PATHFINDER 2 study later this year, further fueling investor enthusiasm about GRAIL's future prospects in early cancer detection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179538506"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179538506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179538506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179538506","market":"sg","top_or_hot":-1,"title":"Stock Track | GRAIL Soars 22.53% on Positive Q1 Results and Encouraging Cancer Detection Trial Data","media":"Stock Track","content":"<p>Shares of GRAIL, Inc. (NASDAQ: GRAL) surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.</p>\n\n<p>GRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million for the quarter, investors were encouraged by the strong top-line growth and the company's improving financial position.</p>\n\n<p>Adding to the optimism, GRAIL announced positive top-line results from the prevalent screening round of the NHS-Galleri trial. The company reported a substantially higher positive predictive value (PPV) than previously observed in the PATHFINDER study. This data suggests improved accuracy in GRAIL's multi-cancer early detection (MCED) technology, potentially strengthening its position in the cancer diagnostics market. The company plans to share registrational data from the PATHFINDER 2 study later this year, further fueling investor enthusiasm about GRAIL's future prospects in early cancer detection.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL Soars 22.53% on Positive Q1 Results and Encouraging Cancer Detection Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL Soars 22.53% on Positive Q1 Results and Encouraging Cancer Detection Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-14 04:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GRAIL, Inc. (NASDAQ: GRAL) surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.</p>\n\n<p>GRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million for the quarter, investors were encouraged by the strong top-line growth and the company's improving financial position.</p>\n\n<p>Adding to the optimism, GRAIL announced positive top-line results from the prevalent screening round of the NHS-Galleri trial. The company reported a substantially higher positive predictive value (PPV) than previously observed in the PATHFINDER study. This data suggests improved accuracy in GRAIL's multi-cancer early detection (MCED) technology, potentially strengthening its position in the cancer diagnostics market. The company plans to share registrational data from the PATHFINDER 2 study later this year, further fueling investor enthusiasm about GRAIL's future prospects in early cancer detection.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1179538506","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179538506","pubTimestamp":1747166693,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GRAIL, Inc.  surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.GRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"股票赛道GRAIL因第一季度业绩积极和癌症检测试验数据令人鼓舞而飙升22.53%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"Shares of GRAIL, Inc. (NASDAQ: GRAL) surged 22.53% during intraday trading on Tuesday following the release of the company's first-quarter 2025 financial results and positive data from its cancer detection trials.\nGRAIL, a healthcare company focused on early cancer detection through blood testing, reported Q1 revenue of $31.8 million, representing a 19% year-over-year growth. The company's flagship product, Galleri, saw its revenue increase by 24% to $29.1 million. Despite posting a net loss of $106.2 million for the quarter, investors were encouraged by the strong top-line growth and the company's improving financial position.\nAdding to the optimism, GRAIL announced positive top-line results from the prevalent screening round of the NHS-Galleri trial. The company reported a substantially higher positive predictive value (PPV) than previously observed in the PATHFINDER study. This data suggests improved accuracy in GRAIL's multi-cancer early detection (MCED) technology, potentially strengthening its position in the cancer diagnostics market. The company plans to share registrational data from the PATHFINDER 2 study later this year, further fueling investor enthusiasm about GRAIL's future prospects in early cancer detection.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}